Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity

Breast cancers regroup many heterogeneous diseases unevenly responding to currently available therapies. Approximately 70–80% of breast cancers express hormone (estrogen or progesterone) receptors. Patients with these hormone-dependent breast malignancies benefit from therapies targeting endocrine p...

Descripción completa

Detalles Bibliográficos
Autores principales: Moisand, Alexandra, Madéry, Mathilde, Boyer, Thomas, Domblides, Charlotte, Blaye, Céline, Larmonier, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606577/
https://www.ncbi.nlm.nih.gov/pubmed/37894728
http://dx.doi.org/10.3390/ijms242015048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606577/
https://www.ncbi.nlm.nih.gov/pubmed/37894728
http://dx.doi.org/10.3390/ijms242015048

Ejemplares similares